Directorate Change

RNS Number:5893T
Tissue Science Laboratories PLC
23 December 2003

                                                                23 December 2003

                    TSL appoints new Technical Director

Aldershot, UK - Tissue Science Laboratories plc (LSE: TSL), the medical devices
company, announces the appointment of Stephen Bloor as Technical Director to the
Board of Directors effective from 17 December 2003.

Stephen Bloor, aged 39, joined the Company in April 2000 as New Product
Development (NPD) Manager and was promoted to Associate Director of NPD in the
latter half of 2002.  He was previously with Johnson & Johnson as Project
Manager of the wound care product development group, and, prior to that, he was
Section Head of Biochemistry at Biocure Limited. In his new role as Technical
Director, Stephen will be responsible for new product development, clinical
research and regulatory affairs and will have Board level responsibility for all
technical matters relating to TSL's current and future products. He has been
performing this function since September and his election represents the Board's
confidence in his ability.

The Company confirms that no other details are required to be disclosed under
Rule 15 and Paragraph F of Schedule 2 of the AIM Rules with respect to Mr Bloor.

                                     -Ends-

Enquiries:

TSL plc                                                  Tel:     [phone]
Martin Hunt, Chief Executive
David Jennings, Finance Director

Hogarth PR                                               Tel:     [phone]
Melanie Toyne-Sewell

Notes to Editors

Background on TSL

Founded in 1995 with headquarters in Aldershot, Hampshire, TSL is a medical
technology company specialising in tissue repair and replacement with a
proprietary sheet product derived from porcine dermis. TSL has launched
successfully two different formulations of the product and built a development
pipeline that addresses the large and fast growing surgical implant and
woundcare markets.  The Company floated in November 2001 and is listed on the
Alternative Investment Market.

TSL has a family of products based on the same core technology.  Each product
has been adapted, with unique properties, to make it suitable for use in
different applications.  PelvicolTM/Permacol Surgical Implant (SI) is sold by
Bard in the US and Europe for urology and gynaecology applications; Permacol SI
(general surgery) is sold for complex hernia repair in the US and Europe;
Permacol SI (ENT, plastic and reconstruction) is sold in Europe for head and
face applications; Permacol Injection (UBA) is an injectable form of Permacol
used as a urethral bulking agent to treat female stress incontinence.  The
Company has also recently signed a worldwide distribution agreement with Zimmer
for the application of Permacol (SI) in the orthopaedic market.  Further
variations of the sheet and injectable forms of Permacol are being developed.

Bard is a trademark of C.R. Bard, Inc. or an affiliate.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOANKNKBCBDKQBB